The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms.
Gut microbiota
anti-PD-1 immunotherapy
commensal microbes
thoracic neoplasms
Journal
Cancer biology & medicine
ISSN: 2095-3941
Titre abrégé: Cancer Biol Med
Pays: China
ID NLM: 101588850
Informations de publication
Date de publication:
07 May 2021
07 May 2021
Historique:
entrez:
7
5
2021
pubmed:
8
5
2021
medline:
8
5
2021
Statut:
aheadofprint
Résumé
Immune checkpoint inhibitors have revolutionized cancer therapy for multiple types of solid tumors, but as expected, a large percentage of patients do not show durable responses. Biomarkers that can predict clinical responses to immunotherapies at diagnosis are therefore urgently needed. Herein, we determined the associations between baseline gut commensal microbes and the clinical treatment efficiencies of patients with thoracic neoplasms during anti-programmed death protein 1 (PD-1) therapy. Forty-two patients with advanced thoracic carcinoma who received anti-PD-1 treatment were enrolled in the study. Baseline and time-serial stool samples were analyzed using 16S ribosomal RNA gene sequencing. Tumor responses, patient progression-free survival, and overall survival were used to measure clinical outcomes. The diversities of the baseline gut microbiota were similar between responders ( Baseline gut microbiota may have a critical impact on anti-PD-1 treatment in thoracic neoplasms. The abundance of gut commensal microbes at diagnosis might be useful for the early prediction of anti-PD-1 immunotherapy responses.
Identifiants
pubmed: 33960176
pii: j.issn.2095-3941.2020.0450
doi: 10.20892/j.issn.2095-3941.2020.0450
pmc: PMC8610161
doi:
pii:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation Fund
ID : 81472559
Organisme : National Natural Science Foundation Fund
ID : 81772490
Organisme : National Key R&D Program of China
ID : 2020YFC2002705
Organisme : National Key R&D Program of China
ID : 2018YFC0115204
Organisme : Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS)
ID : 2016-I2M-1-001
Organisme : Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS)
ID : 2017-I2M-3-004
Organisme : Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS)
ID : 2019-I2M-2-003
Organisme : Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS)
ID : 2019-I2M-1-003
Organisme : CSCO-Hengrui Research Funding
ID : Y-HR2018-239
Informations de copyright
Copyright © 2021 Cancer Biology & Medicine.
Déclaration de conflit d'intérêts
No potential conflicts of interest are disclosed.
Références
Clin Transl Med. 2019 May 13;8(1):16
pubmed: 31081530
Cell Host Microbe. 2008 Oct 16;4(4):337-49
pubmed: 18854238
PLoS One. 2008 Oct 03;3(10):e3326
pubmed: 18833331
Nat Med. 2014 Feb;20(2):159-66
pubmed: 24390308
J Hematol Oncol. 2019 May 2;12(1):47
pubmed: 31046803
Ann Oncol. 2017 Jun 1;28(6):1368-1379
pubmed: 28368458
Cell Host Microbe. 2007 Sep 13;2(3):204
pubmed: 18030708
Int J Neuropsychopharmacol. 2016 Aug 12;19(8):
pubmed: 26912607
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
Int J Syst Evol Microbiol. 2001 Jul;51(Pt 4):1521-1528
pubmed: 11491354
Cancer Biol Med. 2019 Nov;16(4):811-821
pubmed: 31908897
Am Soc Clin Oncol Educ Book. 2019 Jan;39:543-552
pubmed: 31099677
Front Cell Infect Microbiol. 2019 Dec 20;9:434
pubmed: 31956606
J Clin Oncol. 2017 Dec 10;35(35):3924-3933
pubmed: 29023213
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nature. 2019 Jan;565(7741):600-605
pubmed: 30675064
Nucleic Acids Res. 2014 Jan;42(Database issue):D643-8
pubmed: 24293649
NPJ Parkinsons Dis. 2019 Nov 29;5:28
pubmed: 31815177
Nat Rev Clin Oncol. 2018 Jun;15(6):382-396
pubmed: 29636538
Ann Oncol. 2018 Jun 1;29(6):1437-1444
pubmed: 29617710
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Nat Rev Microbiol. 2019 Nov;17(11):701-715
pubmed: 31541196
World J Gastroenterol. 2011 Sep 7;17(33):3761-75
pubmed: 21987618
Nat Methods. 2013 Dec;10(12):1200-2
pubmed: 24076764
PLoS Comput Biol. 2012;8(12):e1002808
pubmed: 23300406
Cancer Biol Med. 2015 Jun;12(2):79-86
pubmed: 26175923
Allergy. 2018 Sep;73(9):1918-1921
pubmed: 29862523
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Clin Transl Med. 2019 Mar 18;8(1):9
pubmed: 30887236
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Biomed Pharmacother. 2017 Nov;95:55-61
pubmed: 28826097
Anaerobe. 2019 Oct;59:159-162
pubmed: 31271773
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Int J Cancer. 2018 Mar 15;142(6):1277-1284
pubmed: 29080213
Am Soc Clin Oncol Educ Book. 2016;35:298-308
pubmed: 27249709
Nat Protoc. 2020 Mar;15(3):799-821
pubmed: 31942082
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
Am J Respir Crit Care Med. 2015 Dec 1;192(11):1335-44
pubmed: 26247840
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Transl Lung Cancer Res. 2017 Jun;6(3):315-324
pubmed: 28713676
mBio. 2019 Apr 2;10(2):
pubmed: 30940698
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
FEMS Microbiol Rev. 2013 Jul;37(4):520-53
pubmed: 23030831
Cancer Biol Med. 2018 May;15(2):116-123
pubmed: 29951336
Science. 2006 Jun 2;312(5778):1355-9
pubmed: 16741115
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998
pubmed: 28446615
J Thorac Oncol. 2019 Aug;14(8):1378-1389
pubmed: 31026576
Science. 2013 Nov 22;342(6161):967-70
pubmed: 24264989
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373